The U.S. Environmental Protection Agency has extended its Emerging Viral Pathogen Guidance for Antimicrobial Pesticides in response to the mpox virus, formerly known as monkeypox.
The EPA originally developed its Emerging Viral Pathogen Guidance back in 2016 specifically to address the growing challenge of emerging infectious pathogens that require rapid public health responses.
Under the guidance, the EPA provides pesticide registrants with a voluntary “two-stage process to enable use of certain EPA-registered disinfectant products against emerging viral pathogens not identified on the product label.”
Many pathogens are absent from product labels because their occurrence is less common and predictable than established pathogens, and because standard laboratory testing methods may not always exist for them.
The EPA’s stated intent is for the guidance to “expedite the process for registrants to provide useful information to the public” regarding products that may be effective against emerging viral pathogens tied to human or animal disease outbreaks.
Registrants that receive a pre-qualified Emerging Viral Pathogen designation are permitted to include efficacy statements in technical literature distributed to health care facilities, physicians, nurses, and public health officials.
That literature can also be shared through non-label-related websites, consumer information services, and social media platforms, broadening the reach of disinfectant guidance during active outbreaks.
Mpox is classified as an enveloped virus, which means it is among the easiest types of viruses to eliminate using an appropriate disinfectant product.
The EPA maintains a searchable resource known as List Q: Disinfectants for Emerging Viral Pathogens, which currently contains 553 disinfectant products approved for use against Tier 1 viruses, the category under which mpox falls.
Because mpox is a Tier 1 enveloped virus, disinfectants that damage its lipid envelope render the virus non-infectious, making a wide range of commercially available products potentially effective.
The EPA first activated its Emerging Viral Pathogen Policy specifically for the mpox virus in August 2024, reflecting the growing public health concern around the disease at that time.
Under the latest extension, the EVP Policy for the mpox virus will now remain active until August 2028, giving registrants and public health communicators a longer window to disseminate relevant product information.
The extension signals a continued commitment by federal regulators to ensure that disinfectant manufacturers and health authorities can communicate effectively during evolving infectious disease situations.
Further information on the mpox virus and its public health implications remains available through the Centers for Disease Control and Prevention’s official website.